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Abstract
Purpose: The current study was undertaken to investigate whether glaucoma affects the sleep quality and whether there is
any difference between patients with primary glaucoma (primary open angle glaucoma, POAG and primary angle-closure
glaucoma, PACG) and healthy subjects, using a validated self-rated questionnaire, the Pittsburgh Sleep Quality Index (PSQI).
Methods: The sleep quality of patients with POAG and PACG was tested against normal controls. Subjects were divided into
three sub-groups according to age. Differences in the frequency of sleep disturbances (PSQI score .7) were assessed. The
differences of sleep quality within the three groups and within the POAG group depending on the patients’ intraocular
pressure (IOP) and impairment of visual field (VF) were also studied.
Results: 92 POAG patients, 48 PACG patients and 199 controls were included. Sleep quality declined with age in control and
POAG group (tendency chi-square, P,0.05). The prevalence of sleep disturbances was higher in POAG and PACG group
than in the control group, the differences were statistically significant. The prevalence of sleep disturbances was higher in
patients with PACG, compared to POAG patients in the age interval of 61–80. In POAG group, the ratio of patients with sleep
disorders increased with augmented impairment of VF, but the differences were not statistically significant (x2-test, P.0.05).
No significant differences were found in POAG group between patients with a highest IOP in daytime and at nighttime (x2-
test, P.0.05).
Conclusions: The prevalence of sleep disorders was higher in patients with POAG and PACG than in controls. PACG patients
seemed to have a more serious problem of sleep disorders than POAG patients between 61 to 80 years old. No correlation
was found between the prevalence of sleep disorders and impairment of VF or the time when POAG patients showed a
highest IOP.
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Introduction
Human eyes mediate both image-forming and non-image-
forming visual functions. Classic photoreceptors including rods
and cones, superior collicular retinal ganglion cells (scRGCs) and
the neurons in the visual cortex are responsible for the image-
forming visual pathway that produce vision. It is now well
established that intrinsically photosensitive retinal ganglion cells
(ipRGCs), a specialized subset of retinal ganglion cells, which
express the photopigment melanopsin, form the retinohypotha-
lamic tract that directly innervate the suprachiasmatic nucleus of
the hypothalamus (SCN) and mediate non-image forming
functions of the eye, including the photoentrainment of circadian
rhythms to the light-dark cycle, the regulation of pupillary light
reflex, negative masking and regulation of melatonin secretion [1–
18].
Glaucoma is the second leading cause of blindness, after
cataract, and the first cause of irreversible blindness worldwide
[19]. This ocular degenerative disease affects the RGCs and
eventually causes optic nerve atrophy, visual impairment and
blindness by way of axonal loss [20].
Recently, the involvement of ipRGCs as well as regular RGCs
in glaucoma has been postulated. Indeed, several studies in animal
models of glaucoma have demonstrated a degenerative loss of
ipRGCs or melanopsin photopigment leading to impairment of
circadian rhythms regulation, pupillary light responses and other
non-image-forming functions [1,11,21–23]. Also, preliminary data
in humans suggested that abnormal circadian rhythm of melatonin
secretion, light-induced melatonin suppression and reduced
pupillary light reflex occur in glaucoma patients [24–26].
Furthermore, a high prevalence of sleep disorders, such as
insomnia, daytime sleep, sleep apnea can be found in patients
with glaucoma [27–31].
Therefore, not only the image-forming visual system, but also
the non-image-forming visual system is associated with glaucoma.
The damage to the latter may have influence on the regulation of
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circadian rhythm and other non-image-forming functions. In
humans, the most characteristic activity of circadian rhythm is the
sleep/wake cycle. Hence, our hypothesis is that in patients with
glaucoma, different degrees of sleep disturbances may occur as a
result of the characteristic damage to ipRGCs. So far, previous
researchers have supported this hypothesis on some level, but
more evidence was warranted. Furthermore, it is still not clear
whether there is any difference in the prevalence of sleep disorders
within glaucoma patients with different degrees of glaucomatous
impairments. Thus, we investigated and compared different
degrees of sleep disturbances among patients with primary open
angle glaucoma (POAG), patients with primary angle-closure
glaucoma (PACG) and normal people without severe ocular or
systemic diseases, using the Pittsburgh Sleep Quality Index (PSQI),
in order to find out changes of sleep quality of glaucoma patients
and possible related factors. The PSQI is a validated self-rated
questionnaire that assesses sleep quality and disturbances during a
period of one month and has been used in many clinical conditions
and researches [32–35]. In PSQI, 19 individual items generate 7
component scores: subjective sleep quality, sleep latency (time
needed to fall asleep), sleep duration, habitual sleep efficiency
(proportion between total sleep time and time in bed), sleep
disturbances (i.e. waking up during night), use of sleeping
medication, and daytime dysfunction (difficulty to stay awake
during the day). The sum of the scores of the 7 items yields a global
score with a possible range of 0–21 [32]. A global PSQI score
higher than 7 yields a diagnostic sensitivity of 98.3% and
specificity of 90.2% (Kappa= 0.89, P,0.01) in distinguishing
good and poor sleepers in Chinese population [34], hence we used
a cutoff score of 7 to consider the existence of sleep disturbances in
our current study.
Methods
Subjects
In this study, 99 patients with POAG and 55 patients with
PACG were recruited consecutively in the Department of
Ophthalmology at Beijing Tongren Hospital, Beijing, China, over
seven months. All the patients were diagnosed by more than two
ophthalmologists in accordance with the diagnostic criteria for
POAG and PACG. A control group of 210 healthy subjects
without any severe systemic or ocular disease were recruited from
Desheng community of Beijing, China, over three months. All
subjects understood the purpose of the study and volunteered to
participate. The subjects were excluded if they have had any kind
of intraocular surgery or laser treatment within three months prior
to this study or if they have a personal history of any other ocular
diseases such as retinitis pigmentosa (RP), systemic diseases
including psychiatric illness, endocrine illness, drug or alcohol
abuse, night work or transmeridian travel in the previous three
months, that might affect the results. Patients with POAG or
PACG were required to have a stable condition including an IOP
lower than 40mmHg in both eyes, no self-discomfort such as
ophthalmalgia, headache, or nausea.
Figure 1. The classification of visual field in POAG patients. *Level 1 =Horizontal stripes, level2 =blank and level 3 =Vertical stripes.
doi:10.1371/journal.pone.0062841.g001
Table 1. Correction values for IOPs based on CCT.
CCT in microns IOP correction in mm Hg
445 +7
455 +6
465 +6
475 +5
485 +4
495 +4
505 +3
515 +2
525 +1
535 +1
545 0
555 21
565 21
575 22
585 23
595 24
605 24
615 25
625 26
635 26
645 27
doi:10.1371/journal.pone.0062841.t001
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Subjects of the three groups were divided according to their age
into any of the three age interval sub-groups, the first being 18 to
40-year-old and the last being 61 to 80-year-old.
Evaluation of the Subjective Sleep Quality
Sleep quality of each subject in the three groups (POAG group,
PACG group and control group) was assessed by means of the
PSQI questionnaire. Sleep was considered to be disturbed if the
global PSQI score was higher than 7. Frequency of sleep
disturbances in each group was assessed. The differences between
either two of the three groups were compared according to the
age-related sub-groups.
Meanwhile, in the POAG group, patients were classified into
three further sub-groups as mild, moderate, and severe visual field
loss, according to their different degrees of visual field loss.
Monocular visual field loss can be graded into four levels,
including no visual field impairment (defined as 0), early-stage
defects such as paracentral scotomas, nasal step defects et al
(defined as 1), advanced-stage defects like arcuate scotoma (defined
as 2) and end-stage defects including a small central island and a
temporal island (defined as 3) [36–37]. The classification of
binocular visual field defects is as following: if the visual field
impairment of one eye is classified to be 0 and the other eye to be
0, 1 or 2, or both eyes 1, then the binocular visual field defects is
graded to be level 1. If the visual field impairment of either eye is
classified to be 2 and the other eye to be 2 or 3, or both eyes 3,
then the binocular visual field defects is graded to be level 3. And
the rest of the conditions are graded to be level 2. All of this
information is shown in Figure 1. Differences between these three
sub-groups were assessed to decide the relationship between sleep
disturbances and impairment of visual field. Moreover, we
evaluated the prevalence of sleep disturbances in patients who
showed a highest intraocular pressure (IOP) in daytime defined as
6:00AM to 10:00PM within the same day and at nighttime defined
as 10:00PM to 6:00AM in the next day in the age groups of 41–60
and 61–80 years old respectively, by means of 24-hour IOP
measurement. This was done to compare the frequency of sleep
disturbances between the two sub-groups within the same age
interval to investigate if IOP is an important factor that affects
sleep quality in POAG patients. It has been proved in previous
studies that IOP was positively related with central corneal
thickness (CCT) [38–40]. Therefore, the actual IOP level of each
Figure 2. Prevalence of sleep disorders (percentage of subjects with PSQI score.7) among people with POAG, PACG and healthy
controls at different age intervals.
doi:10.1371/journal.pone.0062841.g002
Table 2. Demographic data of subjects in POAG, PACG and control group.
Group Total number Number of men Number of women Age (Median (IQR)) (years old)
POAG 92 57 35 58 (41–66)
PACG 48 20 28 65 (60–70)
Control 199 100 99 52 (37–63)
*IQR means interquartile range.
doi:10.1371/journal.pone.0062841.t002
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subject in our research was obtained by correction of IOP
according to CCT, as can be seen in Table 1 [41]. The reason why
POAG patients with an age less than 41 were not included for IOP
analysis is that only 10 patients younger than 41 received 24-hour
IOP measurement.
Statistics
Statistical analysis was performed using SPSS 17.0 for
Windows. Continuous variables were expressed as mean values
6 standard deviation (M 6 SD) and analyzed by using the
independent samples t-tests, one-way ANOVA and nonparametric
test, while categorical variables were presented as frequency and
percentage and were assessed by means of the x2-test and
tendency Chi-square. The level of significance was 0.05 in all
statistical tests.
Results
Eventually, 92 POAG patients, 48 PACG patients and 199
controls with a complete and valid questionnaire were included.
The demographic data of subjects in three groups are shown in
Table 2. Figure 2 shows prevalence of sleep disorders (PSQI score
.7) among subjects affected by POAG and PACG and normal
controls. Table 3 indicates the PSQI total score and percentage of
subjects with sleep disturbances in three sub-groups of different
age intervals of POAG, PACG and controls respectively.
The onset of PACG in patients is often over 40-years-old and
rarely below the age of 30 [19,42]. In this study, there were only
three PACG patients below 40-years-old. Therefore the compar-
ison of PACG patients with POAG patients and controls was
performed over 40-years-old.
According to the analysis, global sleep quality decreased with
age in healthy controls and POAG patients (tendency Chi-square,
P,0.05), as shown in Table 4. And there was no significant
differences in PSQI total score according to gender for controls at
any of the age intervals studied (t-test, P.0.05 in all sub-groups) as
shown in Table 5. As can be seen in Table 6, the prevalence of
sleep disturbances was higher in patients with POAG than in
controls, the differences being statistically significant in each sub-
group (x2-test, P,0.05). And the prevalence of sleep disturbances
was higher in patients with PACG than in controls among sub-
groups of 41–60 and 61–80 age intervals, the differences being
significant (x2-test, P,0.001). Moreover, the prevalence of sleep
disturbances was higher in patients with PACG, compared to
POAG patients in the age interval of 61–80 (x2-test, P,0.05), but
not in the age interval of 41–60 (x2-test, P.0.05).
In the POAG group, the ratio of people with sleep disorders
grew with the augmentation of the visual field impairment, with
the differences not being statistically significant (x2-test, P.0.05),
as can be seen in Table 7. Also, no significant differences were
found between patients with a highest IOP in daytime and patients
with a highest IOP at nighttime in POAG group of both age
intervals (x2-test, P.0.05), as presented in Table 8.
Discussion
There are many sleep assessment methods that include
polysomnography, actiwatch, questionnaire and so on [43–44].
We chose the PSQI, which includes advantages over other
methods such as the ability to: (a) determine patterns of sleep
dysfunction over a 1-month period through assessment of both
qualitative and quantitative data; and (b) calculate a simple global
score that conveys both the number and severity of sleep problems
Table 3. PSQI score and percentage of subjects with PSQI score.7 in six sub-groups among POAG patients, PACG patients and
controls.
Age group
(years old) POAG PACG Controls
TN (M/F) PSQI (M±SD) NPSD (%) TN (M/F) PSQI (M±SD) NPSD (%) TN (M/F) PSQI (M±SD) NPSD (%)
18–40 30(20/10) 7.0062.639 10(33.33%) 3(1/2) 10.3362.309 2(75%) 48(26/22) 4.8362.127 5(10.42%)
41–60 33(21/12) 8.4563.392 16(48.48%) 15(5/10) 10.2063.299 11(73.33%) 64(35/29) 5.6762.637 15(23.44%)
61–80 29(16/13) 8.1362.959 18(62.07%) 33(15/18) 10.4563.280 28(84.85%) 87(39/48) 6.3763.644 27(31.03%)
*TN: total number, M/F: male/female, NPSD: number of patients with sleep disorders.
doi:10.1371/journal.pone.0062841.t003
Table 4. The impact of age on the sleep quality in POAG patients PACG patients and Controls (Tendency Chi-square).
Age
group
(years
old) Controls POAG PACG
NPSD/
NPWSD PPSD P value NPSD/NPWSD PPSD P value
NPSD/
NPWSD PPSD P value
18–40 5/43 10.42% 0.0076 10/20 33.33% 0.0271 Not been analyzed
41–60 15/49 23.44% 16/17 48.48% 11/4 73.33% 0.3434
61–80 27/60 31.03% 18/11 62.07% 28/5 84.85%
Total 47/152 23.62% 44/48 47.83% 39/9 81.25%
*NPSD: number of patients with sleep disorders, NPWSD: number of patients without sleep disorders, PPSD: percentage of patients with sleep disorders.
doi:10.1371/journal.pone.0062841.t004
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[32]. The PSQI has been proved to have adequate reliability, good
validity and high test-retest reliability, and may be used as a
standardized tool for the assessment of subjective sleep quality
among individuals of various ages and has wide clinical and
research applications [33–35,45–46].
The PSQI has been used to assess sleep quality of blind subjects
and patients with ocular diseases [47–49]. Yang and Li
demonstrated that the prevalence of sleep disturbances in patients
with glaucoma was higher when compared to healthy controls
[30]. However, different types of glaucoma were not analyzed
separately and no correlation between IOP or impairment levels of
visual field and prevalence of sleep disturbances was studied.
In our research, we found that global sleep quality decreased
with age in both healthy controls and POAG patients. With
increasing age, the density of the lens increases thereby reducing
light transmission, particularly for the short wavelength (blue) light
to which the circadian system has been shown to be most sensitive
[50]. On the other hand, the occurrence of circadian timing
disturbances with age may also be due to neurodegenerative
changes in the SCN which may cause decreased regulation
function of the non-image-forming system [51].
The prevalence of sleep disorders of POAG and PACG patients
was higher than that of controls within the same age intervals, the
differences being statistically significant. The severe problem of
sleep disturbances of glaucoma patients could be explained by the
reduction of the photic input to the circadian system as a result of
damage of ipRGCs in glaucoma, as the hypothesis that we
proposed. We also found an interesting result that PACG patients
have higher prevalence of sleep disturbances comparing to POAG
patients in the age interval of 61–80. Why is that? There are some
differences in the pathology of PACG and POAG. In some of the
PACG patients, acute IOP elevation (up to 60 mmHg or higher)
can cause ischemic-reperfusion damage to the whole retina,
including not only the ganglion cells, but also other neurons like
rods and cons [52–54]. In POAG, chronic IOP elevation can
cause the ganglion cells apoptosis and axon loss; it has less effect on
other neurons in retina than in PACG. So in PACG, the residual
ipRGCs may get less input from the residual rods and cons. Also,
the mechanisms of RGCs damage in POAG and PACG are
different. This may partially explain the fact mentioned above.
Visual field loss is a manifestation caused by damages of RGCs
in glaucoma. Characteristic visual field impairments include early-
stage defects such as paracentral scotomas, nasal step defects,
enlargement of defects like arcuate scotoma and end-stage defects
including a small central island and a temporal island [55]. In this
study, we found that the ratio of POAG patients with sleep
disorders grew with the aggravation of the impairment of visual
field, but the differences were not statistically significant. In other
words, no correlation was found between the prevalence of sleep
disorders and impairment of visual field in patients with POAG. It
has been suggested that more than 40% of nerve fiber loss happens
before any visual field defect or a change in the optic disc could be
detected in patients with glaucoma [55]. This means that ipRGCs,
as well as other RGCs, might have been damaged before any
visual field loss occurs in patients with glaucoma. Thus, in this
study, different levels of visual field impairment did not represent
significant differences of severity of ipRGCs damage that could
cause different prevalence of sleep disturbances in patients with
POAG. In addition, the negative result may also be attributed to
inadequate number of subjects. Further research should include a
Table 5. T-test for PSQI scores between men and women of different age sub-groups in controls.
Age group
(years old)
Number of
subjects (male)
Number of
subjects (female)
PSQI (M±SD)
(male)
PSQI (M±SD)
(female) P value
18–40 26 22 5.7062.73 5.6362.31 0.905
41–60 35 29 6.6263.55 7.6763.19 0.108
61–80 39 48 7.0663.43 8.2464.19 0.063
doi:10.1371/journal.pone.0062841.t005
Table 6. x2-test for comparison of prevalence of sleep disorder between POAG patients & controls and PACG patients & controls.
Age group (years old) POAG & Control PACG & Control POAG & PACG
P value P value P value
18–40 0.013 Not been analyzed Not been analyzed
41–60 0.012 ,0.001 0.1077
61–80 0.003 ,0.001 0.0408
*PPSD: percentage of patients with sleep disorders.
doi:10.1371/journal.pone.0062841.t006
Table 7. x2-test for POAG patients with different levels of
visual field loss.
Sub-groups
(levels of VF
loss) NPSD NPWSD TN PPSD P value
1 9 16 25 36.00% 0.2361
2 20 22 42 47.62%
3 15 10 25 60.00%
Total number 44 48 92 47.83%
*NPSD: number of patients with sleep disorders, NPWSD: number of patients
without sleep disorders, TN: total number, PPSD: percentage of patients with
sleep disorders.
doi:10.1371/journal.pone.0062841.t007
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larger cohort to reach a conclusive finding of the correlation
between visual field loss and prevalence of sleep disorder in
patients with glaucoma.
Recently, some studies demonstrated that another non-image-
forming visual function is impaired in patients with glaucoma as a
result of ipRGCs loss. Kankipati and colleagues have found that
there is a significant decrease in the ipRGCs-mediated post-
illumination pupil response (PIPR) in glaucoma patients when
compared to age-matched controls [26]. As the severity of the
glaucomatous neuropathy increases, there is a correlated decrease
in the PIPR. Feigl and colleagues also demonstrated that this
phenomenon could be seen in both patients with moderate and
severe glaucoma [56]. These findings together with our results
indicate that non-image-forming visual functions are injured in
clinical glaucoma patients.
In previous studies, sleep disorders of patients with glaucoma
have been attributed to psychological factors or discomforts caused
by an elevated IOP during the night [31]. However, statistical
analysis of our data shows that there is no correlation between the
prevalence of sleep disturbances and the time when patients with
POAG exhibit the highest IOP. This might mean that in a certain
range of IOP, sleep quality may not get affected by elevated IOP
during the night.
Our results clearly show that the sleep quality of patients
suffering from POAG and PACG is significantly decreased. The
reason for this reduction in sleep quality could be found in the
degeneration of ipRGCs mediating the photic input to the SCN in
this disease which may cause damages in non-image-forming
visual pathway and changes of circadian rhythm. Recognition of
this problem provides awareness of the fact that these sets of
patients with glaucoma not only have impairment of visual
functions, but also suffer from sleep disturbances. Therefore, it
may be helpful to improve their sleep quality by treatment with
chronotherapeutic approaches (appropriately-timed exposure to
bright light which may reset the timing of sleep and wake to the
desired times and improve sleep quality), melatonin treatment
which can positively influence comorbid circadian misalignment
and sleep disorders [57–58].
Our study has some limitations that deserve comment. First,
sleep problems were assessed by a self-reporting questionnaire and
were not confirmed by polysomnographic measurements. How-
ever, the PSQI has been largely validated and widely used as a
sufficiently precise tool to discriminate between people with or
without sleep troubles. In future, a more objective index may be
warranted to test the sleep disturbances of glaucoma patients. The
second limitation is that we did not perform the lens grading and
correct the lens density. In our study, 2 patients (4 eyes) in POAG
group, 1 patient (1 eye) in PACG group and 2 controls (4 eyes)
have had IOL implantation. Others have normal lens or slight
cataract, with a visual acuity of 20/60 or better. Another study
showed that, ‘‘No significant differences in sleep quality were
found among RP-patients or controls depending either on their
gender or on the presence of cataracts’’ [48]. So we neglected the
effect of lens on sleep quality in our study. The results will be more
precious with the lens grading. The third limitation concerns the
question of the real relationship between IOP and sleep disorders.
In our study, the highest IOP after correction was below
33mmHg. Hence we couldn’t decide if IOP higher than this
may affect the sleep quality of POAG patients or not. As a result,
more attention should be paid to the conclusion we made, that
within a certain range of IOP, the sleep quality of glaucoma
patients may not be affected by an elevated IOP during night.
Conclusion
Sleep quality declined with age in the control group and the
POAG group. The prevalence of sleep disturbances is higher in
patients with POAG and PACG than healthy controls; the
prevalence of sleep disturbances was higher in patients with
PACG, compared to POAG patients in the age interval of 61–80.
No correlation was found between the prevalence of sleep
disorders and impairment of visual field in POAG patients or
the time when POAG patients showed a highest IOP.
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